地塞米松对非小细胞肺癌化疗患者HIF-1α和VEGF表达的影响及临床意义  

Effect of Dexamethasone on Level of Hypoxia Inducible Factor-1α and Vascular Endothelial Growth Factor in Patients with Non-small Cell Lung Cancer

作　　者：江秀娟[1] 牛继国[1] 呼永华[1] 

机构地区：[1]甘肃省肿瘤医院,甘肃兰州730050

出　　处：《中国肿瘤》2015年第1期73-75,共3页China Cancer

基　　金：甘肃省科技厅技术研究与开发专项计划项目(1105TCYa019)

摘　　要：[目的]探讨地塞米松对非小细胞肺癌化疗患者低氧诱导因子-1α(HIF-1α)和血管内皮生长因子(VEGF)表达的影响。[方法]97例非小细胞肺癌患者随机分为单纯化疗组和地塞米松辅助化疗组,采用酶联免疫吸附试验(ELISA)分别测定两组患者治疗前及治疗后的血清HIF-1α、VEGF水平。[结果]治疗前两组患者HIF-1α及VEGF水平均未见统计学差异(P>0.05);治疗后地塞米松辅助化疗组HIF-1α及VEGF水平明显低于单纯化疗组(P<0.05)。地塞米松辅助化疗组有效率(44.00%)明显高于单纯化疗组(27.79%)(χ2=6.304,P<0.05)。[结论]地塞米松使非小细胞肺癌患者HIF-1α、VEGF水平下降,提高了化疗近期效果。[ Purpose ] To investigate the effeet of dexamethasone on level of hypoxia inducible fac- tors-lot（HIF-lα） and vascular endothelial growth factor （VEGF） in chemotherapy of non-small-cell lung cancer（ NSCLC ）. [Methods] A total of 97 cases with NSCLC were divided into chemother- apy group and combined chemotherapy with dexamethasone . HIF-1α and VEGF level in two groups were detected by enzyme-linked immune sorbent assay in pre - and post-treatment. [Re- sults] The HIF-Icx and VEGF level were not significant difference in two groups before treatment （P〉0.05）. After treatment,the HIF-1α and VEGF level in combined chemotherapy with dexamethasone was lower than that in alone chemotherapy group with significant difference （P〈0.05） .The effective rate in combined chemotherapy with dexamethasone was 44.00% ,which was higher than that in 27.79% in chemotherapy group（X^2=6.304,P〈0.05）. [Conclusion] Dexamethasone can decrease the HIF-1α and VEGF level in patients with NSCLC,improved chemotherapy efficacy.

关 键 词：非小细胞肺癌 地塞米松 低氧诱导因子-1Α 血管内皮生长因子 

分 类 号：R734.2[医药卫生—肿瘤]